Pura Vida Investments

Pura Vida Investments is a private equity firm specializing in the healthcare sector, including biotechnology, medical devices, pharmaceuticals, life sciences, and healthcare services. Founded in 2012 by Efrem Kamen, the firm employs a market-neutral investment strategy to maximize risk-adjusted returns. The firm's portfolio is managed by Efrem Kamen and is run in a market-neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences, and healthcare services.

The firm has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD. The objective of the firm is to generate alpha on both longs and shorts by identifying inflections in company-specific valuations as well as to capitalize on structural changes in the healthcare macro landscape. The firm strives to look past day-to-day volatility and to hone in on major value shifts over the medium to longer term.

The firm's revenue is in the range of $10 million. The firm's SIC code is 6512 - Operators of Nonresidential Buildings. The firm's NAICS code is 5239 - Other Financial Investment Activities. The firm was founded in 2012. The firm has 14 employees. The firm's Chief Financial Officer and Chief Compliance Officer is Alyssa Romano. The firm's Chief Operating Officer is Melissa Balaban. The firm's Head of Business Development is Anne Corey. The firm's Managing Director is Doris Heffernan. The firm's Head of Equities is Matthew Newton.